Fig. 1From: Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institutionKaplan-Meier estimates of treatment-free remission after TKI discontinuation in patients with chronic myeloid leukemia. The estimated survival without molecular relapse (SWMR) at 12 months was 45.4% (95% CI 27.5–63.3) for all patientsBack to article page